Skip to main content
Premium Trial:

Request an Annual Quote

MiRagen Hits First Milestone in Servier microRNA Drug Partnership


MiRagen Therapeutics this week said it has achieved the first milestone in its partnership with Les Laboratoires Servier, with the French company selecting a third target for microRNA drug development.

The move triggered an undisclosed milestone payment to MiRagen.

In late 2011, the companies agreed to jointly develop two of MiRagen’s miRNA antagonists including one designed to silence miR-208 for chronic heart failure and one that targets miR-15/miR-195 to treat post-myocardial infarction remodeling (GSN 11/20/2011).

That deal, which is valued for MiRagen at $45 million over three years — and could be worth up to $1 billion if all clinical and commercial milestones are met — also gave Servier the option to a yet-to-be-named third drug candidate. Now Servier has selected the drug target for that third compound.

Additional details were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.